Clade Therapeutics Announces the Acquisition of Gadeta B.V.
October 02, 2023 08:30 ET
|
Clade Therapeutics
Expands Clade’s pipeline and broadens its platform with:- proprietary gamma/delta (g/d) TCR universal targeting platform technology,- g/d TCR candidate integrated into Clade’s solid tumor pipeline ...
Clade Therapeutics Announces the Appointment of Derek Hei, Ph.D., as Chief Technology Officer
March 10, 2022 08:05 ET
|
Clade Therapeutics
CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Clade Therapeutics, a biopharmaceutical company focused on discovering and delivering scalable, off-the-shelf, next-generation stem cell-based...
Clade Therapeutics Raises $87 Million Series A Financing to Realize the Potential of Cell Therapy
November 03, 2021 07:00 ET
|
Clade Therapeutics
CAMBRIDGE, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Clade Therapeutics, a biopharmaceutical company focused on discovering and delivering scalable, off-the-shelf, next-generation stem cell-based...